

DAFTAR PUSTAKA

- Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018). *Natural Killer Cells: Development, Maturation, and Clinical Utilization*. 9 (August), 1–23.
- Adiputra, P. (2022). *Terapi Primer, Terapi Komplemen, Terapi Alternatif pada Kanker, Apa Bedanya?*. Pelayanan Kesehatan Kementerian Kesehatan.
- Aldarouish, M., Su, X., Qiao, J., Gao, C., Chen, Y., Dai, A., Zhang, T., Shu, Y., & Wang, C. (2019). Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer. *International Journal of Immunopathology and Pharmacology*, 33, 205873841983959.
- Amjad, M. T., Chidharla, A., & Kasi, A. (2023). *Cancer Chemotherapy*. In *StatPearls*. StatPearls Publishing.
- Andriani, H. and Ustiawaty, J., (2020). Metode Penelitian Kualitatif dan Kuantitatif. 1st ed. Yogyakarta: CV Pustaka Ilmu Group Yogyakarta, p.369.
- Arem, H., & Loftfield, E. (2018). *Cancer Epidemiology: A Survey of Modifiable Risk Factors for Prevention and Survivorship*.
- Babic, M., & Romagnani, C. (2018). The role of natural killer group 2, member D in chronic inflammation and autoimmunity. *Frontiers in Immunology*, 9(MAY), 2–7.
- Berben, L., Floris, G., Wildiers, H., & Hatse, S. (2021). Cancer and Aging: Two Tightly Interconnected Biological Processes. *Cancers*, 13(6), 1–20.
- Corkum, C. P., Ings, D. P., Burgess, C., Karwowska, S., Kroll, W., & Michalak, T. I. (2015). Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPTTM) and standard density gradient. *BMC Immunology*, 16(1), 48.
- Dahlan, S., (2018). Langkah-Langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan. 2nd ed. Jakarta: CV Sagung Seto, pp.105-120
- Debela, D. T., Muzazu, S. G. Y., Heraro, K. D., Ndalam, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021). *New approaches and procedures for cancer treatment: Current perspectives*.
- Engel, P., Boumsell, L., Balderas, R., Bensussan, A., Gattei, V., Horejsi, V., Jin, B. Q., Malavasi, F., Mortari, F., Schwartz-Albiez, R., Stockinger, H., van Zelm, M. C., Zola, H., & Clark, G. (2015). CD Nomenclature 2015: Human

- Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. *Journal of immunology (Baltimore, Md: 1950)*, 195(10), 4555–4563.
- Handojo, D., Haryono, S., Sudarsa, I. W., & Panigoro, S. S. (Eds.). (2020). *Panduan Penatalaksanaan Kanker 2020* (2nd ed.). Perhimpunan Ahli Bedah Onkologi Indonesia.
- Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O'Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020). Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ (Clinical Research Ed.)*, 371, m4087.
- Hassona, M. M., Radwan, E. M., Abdelsameea, E., Estaphan, S., Elrhman, H. E. A., Abdel-samiee, M., & Naguib, M. (2021). *The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma*. 22, 2559–2567.
- Hou, H., Luo, Y., Tang, G., Zhang, B., Ouyang, R., Wang, T., Huang, M., Wu, S., Li, D., & Wang, F. (2021). Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy. *Cancer Cell International*, 21(1), 1–11.
- Hultcrantz, R. (2021). Aspects of colorectal cancer screening, methods, age and gender. *Journal of Internal Medicine*, 289(4), 493.
- Huțanu, A., Manu, D., Gabor, M. R., Văsieșiu, A. M., Andrejkovits, A. V., & Dobreanu, M. (2022). Dynamic Evaluation of Natural Killer Cells Subpopulations in COVID-19 Patients. *International Journal of Molecular Sciences*, 23(19).
- Ilic, M., & Ilic, I. (2016). Epidemiology of pancreatic cancer. *World Journal of Gastroenterology*, 22(44), 9694.
- International Agency for Research on Cancer. (2020). *World factsheet Globocan 2020*. 876, 2018–2019.
- Kleiveland, C. R. (2015). Peripheral Blood Mononuclear Cells in The Impact of Food Bioactives on Health: in vitro and ex vivo models. *US National Library of Medicine*, 161-167.
- Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., Henrikson, H. J., Lu, D., Pennini, A., Xu, R., Ababneh, E., Abbasi-Kangevari, M., Abbastabar, H., Abd-Elsalam, S. M., Abdoli, A., Abedi, A., Abidi, H., Abolhassani, H., Adedeji, I. A., ... Force, L. M. (2022). Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic

- Analysis for the Global Burden of Disease Study 2019. *JAMA Oncology*, 8(3), 420–444.
- Leclair, K., Bell, K. J. L., Furuya-Kanamori, L., Doi, S. A., Francis, D. O., & Davies, L. (2021). Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy. *JAMA Internal Medicine*, 181(10), 1351–1358.
- Libert, D., Yuan, C. M., Masih, K. E., Galera, P., Salem, D., Shalabi, H., Yates, B., Delbrook, C., Shern, J. F., Fry, T. J., Khan, J., Stetler-Stevenson, M., & Shah, N. N. (2020). Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. *Leukemia*, 34(11), 3064–3069.
- Li, L., Li, X., Shang, A., Zhao, Y., Jin, L., Zhao, M., & Shen, W. (2022). Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study. *Medicine*, 101(40), E30988.
- Makmun, D., Simadibrata, M., Abdullah, M., Syam, A. F., Shatri, H., Fauzi, A., Renaldi, K., Maulahela, H., Utari, A. P., Pribadi, R. R., Muzellina, V. N., & Nursyirwan, S. A. (2021). Colorectal cancer patients in a tertiary hospital in Indonesia: Prevalence of the younger population and associated factors. *World Journal of Clinical Cases*, 9(32), 9804.
- Mao, J., Zhang, Q., Zhang, H., Zheng, K., Wang, R., & Wang, G. (2020). Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *Frontiers in Endocrinology*, 11, 265.
- Masykura, N., Zaini, J., Syahruddin, E., Andarini, S. L., Hudoyo, A., Yasril, R., Ridwanuloh, A., Hidajat, H., Nurwidya, F., & Utomo, A. (2019). Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients. *Lung Cancer: Targets and Therapy*, 10, 57.
- Mattiuzzi, C., & Lippi, G. (2019). Current Cancer Epidemiology. *Journal of Epidemiology and Global Health*, 9(4), 217.
- Mederos, N., Friedlaender, A., Peters, S., & Addeo, A. (2020). Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. *ESMO Open*, 5(Suppl 4).
- Miller, K. D., Fidler-Benaoudia, M., Keegan, T. H., Hipp, H. S., Jemal, A., & Siegel, R. L. (2020). Cancer statistics for adolescents and young adults, 2020. *CA: A Cancer Journal for Clinicians*, 70(6), 443–459.

- Muharrarah, Z. F., Rohmah, M., & Maulidia, Z. (2022). *Hubungan Tingkat Pendidikan Pasien terhadap Kepatuhan Menjalankan Pengobatan pada Pasien Kanker Mamae di RS Kanker Dharmais Tahun 2021.* 6, 1139–1145.
- Murphy, K., & Weaver, C. (2017). *Janeway's Immunobiology* (9th ed.). Garland Science.
- Nadhira, M., Puspitasari, R. L., Moegni, K. F., Rosadi, I., & Rosliana, I. (2018). *Profil Peripheral Blood Mononuclear Cells (PBMC) Pasien dengan Berbagai Usia Menggunakan Flow Cytometry di Klinik Hayandra* (Vol. 4, Issue 4).
- Paul, S., & Lal, G. (2017). The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. *Frontiers in Immunology*, 8(SEP).
- Prasetyo, D. Y., & Suprayitno, E. (2019). Faktor Kualitas Hidup Pasien Kanker. *Care: Jurnal Ilmiah Ilmu Kesehatan*, 9(2), 322–333.
- Prihantono, Rusli, R., Christeven, R., & Faruk, M. (2023). Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. *Ethiopian Journal of Health Sciences*, 33(3), 515.
- Rébé, C., & Ghiringhelli, F. (2015). Cytotoxic effects of chemotherapy on cancer and immune cells: How can it be modulated to generate novel therapeutic strategies? *Future Oncology*, 11(19), 2645–2654.
- Riskesdas. (2018). Hasil Utama Riskesdas Penyakit Tidak Menular 2018. *Hasil Utama Riskesdas Penyakit Tidak Menular*, 8.
- Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., & Longacre, M. (2013). Cancer Development, Progression, and Therapy: An Epigenetic Overview. *International Journal of Molecular Sciences*, 14(10), 21087–21113.
- Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). *International Journal of Oncology*, 54, 407–419.
- Schubart, J. R., Eliassen, A. H., Schilling, A., & Goldenberg, D. (2021). Reproductive Factors and Risk of Thyroid Cancer in Women: An Analysis in the Nurses' Health Study II. *Women's Health Issues : Official Publication of the Jacobs Institute of Women's Health*, 31(5), 494–502.
- Setiawan, D., Andrijono, Hadinegoro, S. R., Meyta, H., Sitohang, R. V., Tandy, G., Perwitasari, D. A., & Postma, M. J. (2020). Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis. *PLoS ONE*, 15(3).

- Showe, M. K., Kossenkov, A. V., & Showe, L. C. (2013). The peripheral immune response and lung cancer prognosis. *Oncoimmunology*, 1(8), 1414.
- Suraya, A., Nowak, D., Sulistomo, A. W., Icksan, A. G., Berger, U., Syahruddin, E., & Bose-O'reilly, S. (2021). Excess Risk of Lung Cancer Among Agriculture and Construction Workers in Indonesia. *Annals of Global Health*, 87(1), 1–14.
- Tekalign, T., & Teshome, M. (2022). Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis. *PloS One*, 17(4).
- Tesfaw, A., Getachew, S., Addissie, A., Jemal, A., Wienke, A., Taylor, L., & Kantelhardt, E. J. (2021). Late-Stage Diagnosis and Associated Factors Among Breast Cancer Patients in South and Southwest Ethiopia: A Multicenter Study. *Clinical Breast Cancer*, 21(1), e112–e119.
- Tu, Y., Pan, M., Song, S., Hua, J., Liu, R., & Li, L. (2019). CD3+CD56+ natural killer T cell infiltration is increased in cervical cancer and negatively correlated with tumour progression. *Biotechnology & Biotechnological Equipment*, 33(1), 1380–1391.
- Valerio, T. S., Emmerick, I. C. M., & Sobreira-da-Silva, M. J. (2023). Factors associated with late-stage diagnosis and overall survival for lung cancer: An analysis of patients treated in a Brazilian hospital and a US-hospital from 2009 to 2019. *Cancer Epidemiology*, 86.
- Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017). CD56 in the Immune System: More Than a Marker for Cytotoxicity? *Frontiers in Immunology*, 8(JUL), 1.
- Verma, R., Foster, R. E., Horgan, K., Mounsey, K., Nixon, H., Smalle, N., Hughes, T. A., & Carter, C. R. D. (2016). Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. *Breast Cancer Research*, 18(1), 1–12.
- Wahidin, M., Febrianti, R., Susanty, F., & Hasanah, S. R. (2022). Twelve Years Implementation of Cervical and Breast Cancer Screening Program in Indonesia. *Asian Pacific Journal of Cancer Prevention : APJCP*, 23(3), 829–837.
- Wang, W., Wang, Y., & Cao, Z. (2021). Changes of proportions of circulating lymphocyte subsets in cancer patients after chemotherapy. *Translational Cancer Research*, 10(9), 4169–4179.
- Weber, E. W., Maus, M. V., & Mackall, C. L. (2020). The Emerging Landscape of Immune Cell Therapies. In *Cell* (Vol. 181, Issue 1, pp. 46–62). Cell Press.

- Yang, J., Li, P., Piao, Y., Liu, X., Wei, L., Sang, W., Zhang, L., & Wang, L. (2022). CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase. *Frontiers in Immunology*, 13, 1.
- Yoda, S., & Theeke, L. A. (2022). A Scoping Review of Factors Contributing to Late-Stage Diagnosis of Breast Cancer in Racial and Ethnic Minority (African American and Hispanic) Women. *SAGE Open*, 12(4).
- Zhou, J., Lin, H. P., Xu, X., Wang, X. H., Rong, L., Zhang, Y., Shen, L., Xu, L., Qin, W. T., Ye, Q., Ma, X. M., & Bai, Y. R. (2022). The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy. *Frontiers in Immunology*, 13, 1041126.